FDA OKs trials for experimental Ebola drug to begin in Liberia
The maker of an
experimental drug cocktail that has helped several people infected with the
Ebola virus recover announced Feb. 27 that the U.S. Food and Drug Administration
has given approval for controlled clinical trials to begin in Liberia.
Developed by San
Diego-based Mapp Biopharmaceutical Inc., ZMapp is comprised of three
antibodies, which are manufactured in tobacco plants.
"Although
ZMapp has been used to treat several Ebola-infected patients in recent months,
we cannot determine if the drug actually benefited those patients because it
was not administered within the context of a clinical trial," Dr. Anthony
Fauci, director of the National Institute of Allergy and Infectious Diseases,
said in a press release.
No comments:
Post a Comment